Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $68.5 million.

  • Voyager Therapeutics' Total Liabilities fell 2846.0% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year decrease of 2846.0%. This contributed to the annual value of $93.3 million for FY2024, which is 1885.07% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Total Liabilities is $68.5 million, which was down 2846.0% from $78.2 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Total Liabilities registered a high of $148.3 million during Q1 2022, and its lowest value of $68.5 million during Q3 2025.
  • Moreover, its 5-year median value for Total Liabilities was $100.8 million (2024), whereas its average is $104.8 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first crashed by 5820.15% in 2021, then surged by 4604.71% in 2022.
  • Over the past 5 years, Voyager Therapeutics' Total Liabilities (Quarter) stood at $98.8 million in 2021, then rose by 1.55% to $100.3 million in 2022, then increased by 14.58% to $115.0 million in 2023, then dropped by 18.85% to $93.3 million in 2024, then dropped by 26.59% to $68.5 million in 2025.
  • Its last three reported values are $68.5 million in Q3 2025, $78.2 million for Q2 2025, and $80.5 million during Q1 2025.